BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

117 related articles for article (PubMed ID: 32025577)

  • 1. Immunological microenvironment gene expression in patients with diffuse large B cell non Hodgkin lymphoma.
    Elhelbawy NG; Nassar AAH; Eltorgoman AEA; Saber SM; Badr EA
    Biochem Biophys Rep; 2020 Mar; 21():100731. PubMed ID: 32025577
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Correlation between FOXP3, CD11c Protein Expression and Prognosis of Patients with Diffuse Large B-cell Lymphoma].
    Li YB; Wang Z; Zuo HB; Li LB
    Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2021 Feb; 29(1):104-108. PubMed ID: 33554805
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Clinicopathologic significance of tumor microenvironment CD11c, and FOXP3 expression in diffuse large B-cell lymphoma patients receiving rituximab, cyclophosphamide, anthracycline, vincristine, and prednisone (R-CHOP) combination chemotherapy.
    Lee S; Kim DH; Oh SY; Kim SY; Koh MS; Lee JH; Lee S; Kim SH; Kwak JY; Pak MG; Ju MH; Kim HJ; Jeong JS
    Korean J Intern Med; 2017 Mar; 32(2):335-344. PubMed ID: 26968188
    [TBL] [Abstract][Full Text] [Related]  

  • 4. PD-1/PD-L1 Pathway and Its Blockade in Patients with Classic Hodgkin Lymphoma and Non-Hodgkin Large-Cell Lymphomas.
    Xie W; Medeiros LJ; Li S; Yin CC; Khoury JD; Xu J
    Curr Hematol Malig Rep; 2020 Aug; 15(4):372-381. PubMed ID: 32394185
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Non-Hodgkin lymphomas: impact of rituximab on overall survival of patients with diffuse large B-cell and follicular lymphoma.
    Jaime-Pérez JC; Gamboa-Alonso CM; Vázquez-Mellado de Larracoechea A; Rodríguez-Martínez M; Gutiérrez-Aguirre CH; Marfil-Rivera LJ; Gómez-Almaguer D
    Arch Med Res; 2015 Aug; 46(6):454-61. PubMed ID: 26235285
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Clinicopathologic characteristics and outcome of diffuse large B-cell lymphomas presenting with an associated low-grade component at diagnosis.
    Ghesquières H; Berger F; Felman P; Callet-Bauchu E; Bryon PA; Traverse-Glehen A; Thieblemont C; Baseggio L; Michallet AS; Coiffier B; Salles G
    J Clin Oncol; 2006 Nov; 24(33):5234-41. PubMed ID: 17043351
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Intratumoral FOXP3+ Regulatory T Cells in Diffuse Large B-Cell Lymphoma.
    Serag El-Dien MM; Abdou AG; Asaad NY; Abd El-Wahed MM; Kora MAEM
    Appl Immunohistochem Mol Morphol; 2017 Sep; 25(8):534-542. PubMed ID: 26862953
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prognostic implications of the tumor immune microenvironment and immune checkpoint pathway in primary central nervous system diffuse large B-cell lymphoma in the North Indian population.
    Parkhi M; Chatterjee D; Bal A; Vias P; Yadav BS; Prakash G; Gupta SK; Radotra BD
    APMIS; 2022 Feb; 130(2):82-94. PubMed ID: 34862664
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Evaluation of a five-gene signature associated with stromal infiltration for diffuse large B-cell lymphoma.
    Nan YY; Zhang WJ; Huang DH; Li QY; Shi Y; Yang T; Liang XP; Xiao CY; Guo BL; Xiang Y
    World J Clin Cases; 2021 Jun; 9(18):4585-4598. PubMed ID: 34222425
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diffuse large B-cell lymphoma and mantle cell lymphoma of the ocular adnexal region, and lymphoma of the lacrimal gland: an investigation of clinical and histopathological features.
    Rasmussen PK
    Acta Ophthalmol; 2013 Jul; 91 Thesis 5():1-27. PubMed ID: 24041159
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The Dark Side of Pyroptosis of Diffuse Large B-Cell Lymphoma in B-Cell Non-Hodgkin Lymphoma: Mediating the Specific Inflammatory Microenvironment.
    Wang W; Xu SW; Teng Y; Zhu M; Guo QY; Wang YW; Mao XL; Li SW; Luo WD
    Front Cell Dev Biol; 2021; 9():779123. PubMed ID: 34805183
    [No Abstract]   [Full Text] [Related]  

  • 12. The Role of Lymphocyte to Monocyte Ratio, Microvessel Density and HiGH CD44 Tumor Cell Expression in Non Hodgkin Lymphomas.
    Jelicic J; Balint MT; Jovanovic MP; Boricic N; Micev M; Stojsic J; Antic D; Andjelic B; Bila J; Balint B; Pavlovic S; Mihaljevic B
    Pathol Oncol Res; 2016 Jul; 22(3):567-77. PubMed ID: 26750138
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Epstein-Barr virus-positive diffuse large B-cell lymphoma association is not only restricted to elderly patients.
    Cohen M; Narbaitz M; Metrebian F; De Matteo E; Preciado MV; Chabay PA
    Int J Cancer; 2014 Dec; 135(12):2816-24. PubMed ID: 24789501
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical prognostic factors of diffuse large B cell non-Hodgkin lymphoma: a retrospective study.
    Abdelhamid T; Samra M; Ramadan H; Mehessin M; Mokhtar N
    J Egypt Natl Canc Inst; 2011 Mar; 23(1):17-24. PubMed ID: 22099932
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [A retrospective analysis of clinical characteristics and prognostic factors for 124 cases of primary gastric lymphomas].
    He Y; Wang L; Zhu HY; Liang JH; Wu W; Wu JZ; Xia Y; Cao L; Fan L; Li JY; Xu W
    Zhonghua Xue Ye Xue Za Zhi; 2017 Jun; 38(6):505-510. PubMed ID: 28655094
    [No Abstract]   [Full Text] [Related]  

  • 16. [The relationship between Sjogren's syndrome, systemic sclerosis and lymphoproliferative diseases].
    Vasil'ev VI; Chal'tsev BD; Gorodetskii VR; Pal'shina SG; Shornikova NS; Anan'eva LP; Gaiduk IV; Kokosadze NV; Probatova NA; Pavlovskaia AI; Rodionova EB; Safonova TN; Balabina AA
    Ter Arkh; 2020 Dec; 92(12):126-136. PubMed ID: 33720584
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Programmed death ligand 1 is expressed by non-hodgkin lymphomas and inhibits the activity of tumor-associated T cells.
    Andorsky DJ; Yamada RE; Said J; Pinkus GS; Betting DJ; Timmerman JM
    Clin Cancer Res; 2011 Jul; 17(13):4232-44. PubMed ID: 21540239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. High PTX3 expression is associated with a poor prognosis in diffuse large B-cell lymphoma.
    Carreras J; Kikuti YY; Hiraiwa S; Miyaoka M; Tomita S; Ikoma H; Ito A; Kondo Y; Itoh J; Roncador G; Martinez A; Colomo L; Hamoudi R; Ando K; Nakamura N
    Cancer Sci; 2022 Jan; 113(1):334-348. PubMed ID: 34706126
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The Impact of IL-6 and IL-10 Gene Polymorphisms in Diffuse Large B-Cell Lymphoma Risk and Overall Survival in an Arab Population: A Case-Control Study.
    Al-Khatib SM; Abdo N; Al-Eitan LN; Al-Mistarehi AH; Zahran DJ; Kewan TZ
    Cancers (Basel); 2020 Feb; 12(2):. PubMed ID: 32046104
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.